Search results
Showing 6301 to 6350 of 8914 results
Recommendation ID NG212/05 Question Core outcomes for study reporting: Which mental wellbeing and productivity outcomes should be used
Recommendation ID NG162/1 Question Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are
Recommendation ID NG103/4 Question Opt-out strategies for front-line health and social care staff:- Are opt-out strategies effective and
Recommendation ID NG88/5 Question Second-generation endometrial ablation for HMB associated with myometrial pathology:- Are outcomes after
Recommendation ID NG161/1 Question Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and
Recommendation ID NG143/08 Question Signs and symptoms of Kawasaki disease: Which signs and symptoms (or combinations of signs and symptoms)
Recommendation ID NG94/8 Question Primary care-led assessment models:- Which primary care-led models of assessment of people with a suspected
Online help programme recommended for people with eating disorders
An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said.
Thousands living with lupus offered hope from twice-yearly infusion
NICE approves breakthrough combination treatment that restores normal kidney function in almost half of patients with lupus nephritis.
Thousands could benefit from new take-at-home treatment for advanced prostate cancer
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment.
New hope for people with breathing condition, COPD, as NICE approves innovative treatment
Breakthrough therapy reduces flare-ups by almost a third and could ease pressure on NHS hospitals.
Home News Podcasts The asthma guideline – one year on Podcasts 29 January 2026 Listen About this episode Developed collaboratively by the
Reviewing 2025: Producing faster rigorous guidance to make an impact on patients' lives
Home News Podcasts Reviewing 2025: Producing faster rigorous guidance to make an impact on patients' lives Podcasts 17 December 2025 Listen
Getting medicines to NHS patients faster with aligned decisions with the MHRA
Home News Podcasts Getting medicines to NHS patients faster with aligned decisions with the MHRA Podcasts 12 November 2025 Listen About this
NICE says paperclip-sized sensor could help thousands monitor heart condition from home
A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before they become emergencies, NICE has said.
Simple home test prevents thousands of unnecessary bowel cancer referrals
A simple home test is sparing thousands of people from unnecessary hospital investigations for bowel cancer, while helping them get faster answers about whether they have the disease – with new data showing the impact of NICE's recommendation to use the test.
Faster, fairer access to HealthTech under new national programme
People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).
Hidden spine fractures could be spotted earlier after NICE recommendation
NICE is recommending that quick spine checks are added to routine bone scans to help spot hidden fractures earlier and prevent serious complications.
Digital platforms recommended to help people manage their asthma
People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier
More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.
NICE recommends new treatment option for highly active multiple sclerosis
Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.
NICE announces Professor Jonathan Benger as new Chief Executive
NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]
Discontinued Reference number: GID-TA10354
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]
Discontinued Reference number: GID-TA10355
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]
Discontinued Reference number: GID-TA10356
Nintedanib for untreated malignant pleural mesothelioma [ID1424]
Discontinued Reference number: GID-TA10359
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
Discontinued Reference number: GID-TA10363
Discontinued Reference number: GID-TA10365
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]
Discontinued Reference number: GID-TA10382
Discontinued Reference number: GID-TA10390
In development Reference number: GID-TA10391 Expected publication date: TBC
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued Reference number: GID-TA10394
Discontinued Reference number: GID-TA10395
Discontinued Reference number: GID-TA10397
Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]
Discontinued Reference number: GID-TA10401
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
Discontinued Reference number: GID-TA10402
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
In development Reference number: GID-TA10404 Expected publication date: TBC
In development Reference number: GID-TA10405 Expected publication date: TBC
Discontinued Reference number: GID-TA10413
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
Discontinued Reference number: GID-TA10416
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
Discontinued Reference number: GID-TA10422
Discontinued Reference number: GID-TA10425
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued Reference number: GID-TA10427
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
Discontinued Reference number: GID-TA10527
Discontinued Reference number: GID-TA10531
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Discontinued Reference number: GID-TA10536